Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

Table 1

Regression of RN on fundus examination with absence of fluorescein leakage after IVB at 24 months*.

RN Regression	Unresponsive Neovascularization		Naive Neovascularization		Total eyes
	2.5 mg	1.25 mg	2.5 mg	1.25 mg
Total	5	7	2	3	17 (39.5%)
Partial	4	7	2	2	15 (34.9%)
No.	3	5	2	1	11 (25.6%)
Total eyes	12	19	6	6	43 (100%)

*RN: Retinal neovascularization, IVB: Intravitreal bavacizumab.